ZA969831B - Solid mixtures of cyclodextrins prepared via melt-extrusion. - Google Patents

Solid mixtures of cyclodextrins prepared via melt-extrusion.

Info

Publication number
ZA969831B
ZA969831B ZA9609831A ZA969831A ZA969831B ZA 969831 B ZA969831 B ZA 969831B ZA 9609831 A ZA9609831 A ZA 9609831A ZA 969831 A ZA969831 A ZA 969831A ZA 969831 B ZA969831 B ZA 969831B
Authority
ZA
South Africa
Prior art keywords
extrusion
prepared via
solid mixtures
via melt
cyclodextrins prepared
Prior art date
Application number
ZA9609831A
Other languages
English (en)
Inventor
Lieven Elvire Colette Baert
Jozef Peeters
Geert Verreck
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26139823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA969831(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA969831B publication Critical patent/ZA969831B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA9609831A 1995-11-23 1996-11-22 Solid mixtures of cyclodextrins prepared via melt-extrusion. ZA969831B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95203219 1995-11-23
US09/081,808 US6365188B1 (en) 1995-11-23 1998-05-20 Solid mixtures of cyclodextrins prepared via meltextrusion

Publications (1)

Publication Number Publication Date
ZA969831B true ZA969831B (en) 1998-05-22

Family

ID=26139823

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9609831A ZA969831B (en) 1995-11-23 1996-11-22 Solid mixtures of cyclodextrins prepared via melt-extrusion.

Country Status (16)

Country Link
US (1) US6365188B1 (pl)
EP (1) EP0862463A1 (pl)
JP (1) JP3310299B2 (pl)
CN (1) CN1198655C (pl)
AU (1) AU725204B2 (pl)
BR (1) BR9611562A (pl)
CZ (1) CZ154398A3 (pl)
HU (1) HUP9900730A3 (pl)
IL (1) IL123654A (pl)
NO (1) NO981078L (pl)
NZ (1) NZ322907A (pl)
PL (1) PL189122B1 (pl)
SK (1) SK67298A3 (pl)
TR (1) TR199800729T2 (pl)
WO (1) WO1997018839A1 (pl)
ZA (1) ZA969831B (pl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189122B1 (pl) * 1995-11-23 2005-06-30 Janssen Pharmaceutica Nv Sposób wytwarzania mieszaniny stałej zawierającejjedną lub wiele cyklodekstryn, mieszanina stała ikompozycja farmaceutyczna
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
PT1033975E (pt) * 1997-11-28 2002-07-31 Knoll Ag Processo para a preparacao de substancias biologicamente activas nao-cristalinas isentas de dissolventes
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
EA004049B1 (ru) 1998-11-10 2003-12-25 Янссен Фармацевтика Н.В. Пиримидины, ингибирующие репликацию вич
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
DE19911097A1 (de) * 1999-03-12 2000-09-14 Basf Ag Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen
BR0009176A (pt) 1999-03-24 2001-12-18 Fmc Corp Partìcula granular, forma de dosagem, métodopara preparar uma partìcula granular, misturaseca, e, formulação granular
CZ20013866A3 (cs) 1999-05-04 2002-06-12 Janssen Pharmaceutica N. V. Antifungální ethery
FR2803748A1 (fr) * 2000-01-14 2001-07-20 Ethypharm Lab Prod Ethiques Composition d'itraconazole et procede de preparation
ATE414079T1 (de) 2000-03-01 2008-11-15 Janssen Pharmaceutica Nv 2,4-disubstituierte thiazolyl derivate
US6835717B2 (en) * 2000-03-08 2004-12-28 The Johns Hopkins University School Of Medicine β-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases
US7276510B2 (en) 2000-05-08 2007-10-02 Janssen Pharmaceutica, Inc. HIV replication inhibitors
ITRN20000051A1 (it) 2000-12-22 2002-06-22 Ascor Chimici Srl Metodo e apparecchiatura per formare sferule composite contenenti principi attivi del tipo farmaceutico e/o integratori alimentari o cosmeti
GB0113841D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
WO2003015773A2 (en) 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. 2-amino-4,5-trisubstituted thiazolyl derivatives and their use against autoimmune diseases
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
MXPA04007776A (es) 2002-03-13 2004-10-15 Janssen Pharmaceutica Nv Derivados de sulfonilamino como nuevos inhibidores de histona deacetilasa.
EP1485353B1 (en) 2002-03-13 2011-08-24 Janssen Pharmaceutica NV New inhibitors of histone deacetylase
AU2003266413B2 (en) 2002-08-09 2009-04-02 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
MXPA05008364A (es) 2003-02-07 2005-11-04 Janssen Pharmaceutica Nv Derivados de pirimidina para la prevencion de una infeccion por vih.
PL232814B1 (pl) 2003-02-07 2019-07-31 Janssen Pharmaceutica Nv Pochodne 1,2,4-triazynowe, ich zastosowanie i zawierająca je kompozycja farmaceutyczna
CL2004000306A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
CA2520522C (en) * 2003-03-28 2012-05-29 Ivax Corporation Cladribine formulations for improved oral and transmucosal delivery
BRPI0408848B8 (pt) * 2003-03-28 2021-07-27 Ares Trading Sa composições farmacêuticas de complexo de ciclodextrina-cladribina complexo, usos do referido complexo, bem como processos para a sua preparação
AU2004274185B2 (en) 2003-09-25 2009-12-10 Janssen Pharmaceutica N.V. HIV replication inhibiting purine derivatives
US20050118265A1 (en) * 2003-11-28 2005-06-02 Anandi Krishnan Antifungal oral dosage forms and the methods for preparation
AP2336A (en) 2004-07-28 2011-12-08 Janssen Pharmaceutica Nv Subsituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase.
WO2006015985A1 (en) 2004-08-10 2006-02-16 Janssen Pharmaceutica N.V. Hiv inhibiting 1,2,4-triazin-6-one derivatives
AU2005288866B2 (en) 2004-09-30 2012-07-26 Janssen Sciences Ireland Uc HIV inhibiting 5-substituted pyrimidines
ES2371923T3 (es) 2004-09-30 2012-01-11 Tibotec Pharmaceuticals 5-heterociclil-pirimidinas que inhiben el vih.
EP1807430B1 (en) 2004-10-29 2014-07-23 Janssen R&D Ireland Hiv inhibiting bicyclic pyrimidine derivatives
AU2006208778B2 (en) 2005-01-27 2012-08-09 Janssen Sciences Ireland Uc HIV inhibiting 2-( 4-cyanophenylamino) pyrimidine derivatives
RS51435B (en) 2005-03-04 2011-04-30 Tibotec Pharmaceuticals 2- (4-CYANOPHENYL) -6-HYDROXYLAMINOPYRIMIDINE INHIBITING HIV
DK1912626T3 (en) * 2005-08-08 2016-08-01 Abbvie Deutschland Dosage forms with improved bioavailability
US20070082870A1 (en) * 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
CA2630717C (en) 2006-01-19 2015-02-24 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
EP1832281A1 (en) 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Process for producing a solid dispersion of an active ingredient
DE602007009508D1 (de) 2006-03-30 2010-11-11 Little Island Co Cork Hiv-inhibierende 5-(hydroxymethylen- und aminomethylen) substituierte pyrimidine
EP2004632B1 (en) 2006-03-30 2014-03-12 Janssen R&D Ireland Hiv inhibiting 5-amido substituted pyrimidines
KR20090094084A (ko) 2006-12-29 2009-09-03 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 억제하는 5,6-치환된 피리미딘
ES2470570T3 (es) 2006-12-29 2014-06-24 Janssen R&D Ireland Pirimidinas sustituidas en posición 6 inhibidoras del HIV
WO2009134848A1 (en) * 2008-04-30 2009-11-05 Novartis Ag Continuous process for making pharmaceutical compositions
CN102438578A (zh) 2009-05-07 2012-05-02 基伊埃制药系统有限公司 药片生产模块和用于连续生产药片的方法
US20120148678A1 (en) 2010-12-08 2012-06-14 Advanced Technologies And Regenerative Medicine, Llc. Sustained release of poorly water soluble active compounds
US10532102B2 (en) 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
CN107441504A (zh) * 2017-09-06 2017-12-08 广州中医药大学 番茄红素包合物及其制备方法及番茄红素包合物片剂、胶囊和颗粒
CN110898015A (zh) * 2019-12-31 2020-03-24 上海汉维生物医药科技有限公司 一种伊曲康唑制剂的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61152765A (ja) * 1984-12-27 1986-07-11 Nippon Ekishiyou Kk シクロデキストリン類で包接された化合物を含有した合成樹脂製品及びその製造方法
US5009900A (en) * 1989-10-02 1991-04-23 Nabisco Brands, Inc. Glassy matrices containing volatile and/or labile components, and processes for preparation and use thereof
JP2616251B2 (ja) * 1992-10-14 1997-06-04 日本新薬株式会社 結晶状態の転移方法
AU5376994A (en) * 1992-11-10 1994-06-08 Nippon Shinyaku Co. Ltd. Enclosure compound manufacturing method
FR2705677B1 (fr) * 1993-05-28 1995-08-11 Roquette Freres Micro-granules obtenus par extrusion-sphéronisation contenant une cyclodextrine.
PL189122B1 (pl) * 1995-11-23 2005-06-30 Janssen Pharmaceutica Nv Sposób wytwarzania mieszaniny stałej zawierającejjedną lub wiele cyklodekstryn, mieszanina stała ikompozycja farmaceutyczna
KR100331529B1 (ko) 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법

Also Published As

Publication number Publication date
NZ322907A (en) 1998-12-23
EP0862463A1 (en) 1998-09-09
TR199800729T2 (xx) 1998-07-21
SK67298A3 (en) 1998-11-04
IL123654A (en) 2001-08-08
AU7694396A (en) 1997-06-11
CN1198655C (zh) 2005-04-27
NO981078D0 (no) 1998-03-11
PL326161A1 (en) 1998-08-31
WO1997018839A1 (en) 1997-05-29
JP3310299B2 (ja) 2002-08-05
US6365188B1 (en) 2002-04-02
BR9611562A (pt) 1999-03-02
HUP9900730A2 (hu) 1999-07-28
CZ154398A3 (cs) 1998-08-12
CN1200677A (zh) 1998-12-02
AU725204B2 (en) 2000-10-05
PL189122B1 (pl) 2005-06-30
IL123654A0 (en) 1998-10-30
NO981078L (no) 1998-05-22
HUP9900730A3 (en) 2001-04-28
JPH11501050A (ja) 1999-01-26

Similar Documents

Publication Publication Date Title
ZA969831B (en) Solid mixtures of cyclodextrins prepared via melt-extrusion.
ZA961444B (en) Pyrazolylbenzoyl derivatives.
ZA9610858B (en) Heteroclyclic compounds.
AU4006495A (en) Vibrating catheter
MX213417B (es) Fenilpiridazinonas.
ZA964468B (en) Triazolylmethyl-cyclopentanols.
ZA961449B (en) Isoxazolylbenzoyl derivatives.
ZA961955B (en) Indazolecarboxamides.
ZA969221B (en) Indolealkyl derivatives of benzodioxanmethylamine.
AU7333096A (en) Crib
ZA969973B (en) 2-thioxo-imidazolidin-4-one derivatives.
AU6123196A (en) N-aryl-1,2,4-triazolin-5-ones
DE69610844D1 (en) Hydroformylierungsverfahren.
HUP9900506A3 (en) Prothrombin derivatives
ZA962821B (en) 4-indolylpiperazinyl derivatives.
ZA967357B (en) Pyrazol-4-ylbenzoyl derivatives.
AU4319997A (en) Deodorizing substance
ZA964034B (en) N-aminopyridone derivatives.
AUPN728495A0 (en) Drier
ZA964264B (en) Retinoid-like compounds.
ZA969560B (en) Substituted 1-methyl-3-phenylpyrazoles.
AU6242996A (en) Uricosuric agent
AU696576B2 (en) 4-amino-5-oxy-2,6,6-trimethyl-2-cycloheptene compounds
ZA967181B (en) Substituted Benzylaminopiperidine Compounds.
ZA977035B (en) Modified oligosaccharides.